Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-LEUKEMIA: Metformin as leukemia-preventive therapy in CCUS or lower-risk MDS
2020-005088-30Phase 2Active
- Sponsor
- Kirsten Grønbæk
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of metformin in clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndrome (MDS), sponsored by Kirsten Grønbæk. Primary endpoints: Safety of metformin in CCUS and LR-MDS (WP1) and Feasibility of study protocol (WP1). Started Nov 2020; status: active.
02
Drugs
metformin
03
Conditions
clonal cytopenia of undetermined significance (CCUS)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-005088-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005088-30.